OmniCyte Founder, Peter Leonardi, provides insight into the emerging field of immunotherapy. Immunotherapy is the process that uses the body’s natural defense system to cure cancer. The most popular area is in […]
Motley Fool: Oncolytics – Cancer Killing Virus enters Phase II Metastatic Melanoma Trial
A unique drug is on the right pathway to success, as Oncolytics Biotechnology (ONCY) is pushing Reolysin through the pipeline. David Williamson from Motley Fool reported that this cancer medication is based off a common virus, incidentally referred to as the new “Cancer-Killing Virus.”
DelMar IPO Obscurity Could Offer Investors Favorable Entry
DelMar Pharmaceuticals (DMPI.OB) started 2013 with a revealing corporate update on January 8th. In the update, president and CEO Jeffrey Bacha outlined his goals with an exciting year ahead for the company and its employees. Mr. Bacha focused primarily on the company’s lead product candidate, VAL-083, a small molecule (chemotherapy) agent that DelMar is developing in a dose escalation trial for recurrent glioblastoma multiforme (GBM).
Actium BioSystems: Revolutionizing Drug Delivery for Oncology Hyperthermia
WHAT IF there were a way to give cancer a ‘fever’ to enhance the results of chemotherapy and radiation? There is, says Actium BioSystems…
Smart Stocks Watch: Atossa Genetics — FDA-Approved Diagnostic Test for Breast Cancer
Atossa Genetics [Nasdaq: ATOS] is a healthcare company focused on the development and marketing of novel cellular and molecular diagnostic risk assessment products for breast cancer through the detection of precursors to breast cancer.
Your Biotech Calendar, August 28: PDUFA Dates, SEC Filings, Financings
At OneMedPlace, our goal is to be your eyes and ears to the biotech and life sciences sector: putting into perspective what we’ve seen so far, and providing you with snapshots of and what’s upcoming.
OneMedRadio: Dr. Daniel Teper of Immune Pharmaceuticals on the Power of Monoclonal Antibodies
IMMUNE Pharmaceuticals is an Israeli and US based emerging leader in the development of antibody therapeutics in cancer and inflammation. IMMUNE has multiple drug candidates based on proprietary cytotoxic formulations, linkers and monoclonal antibodies.
OncoSec Closes $7.75 Million Public Offering
OncoSec intends to use proceeds from the offering for general corporate purposes, including clinical trial expenses and research and development expenses.